Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07135323 · ClinicalTrials.gov registry record
AvertD Post-Approval Study
A clinical trial of Opioid Use Disorder, sponsored by Prescient Medicine Holdings.
- Recruiting
- Registry status
- 4,000
- Enrollment target
- 1
- Study location
NCT07135323: Recruiting study of Opioid Use Disorder, sponsored by Prescient Medicine Holdings.
NCT07135323 is a study of Opioid Use Disorder that is actively recruiting participants, run by Prescient Medicine Holdings. The registered enrollment target is 4,000 participants, below the 4,641-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (14% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07135323, a study of Opioid Use Disorder, is actively recruiting participants, sponsored by Prescient Medicine Holdings.
- RECRUITING
- Registry status
- 4,000 participants
- Enrollment target
- 1
- Study location
Study Summary
A Prospective Post-Approval Study of AvertD to Evaluate Device Performance, Prescribing Impact, and Labeling Comprehension in the Intended Use Population
Primary Outcome
Comparison of Averted results to diagnosis of Opioid Used Disorder from M.I.N.I. tool
Conditions Studied
Interventions
- GENETIC Opioid Used Disorder Risk Assessment
Study Locations (1)
Indiana
- Concentrics Research - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,000 participants |
| Start Date | 2024-11-15 |
| Est. Completion | 2031-11 |
What NCT07135323 shows while recruiting
NCT07135323 is an observational study that tracks outcomes without assigning an intervention. Its 4,000 participants enrollment target places it among the larger protocols in the corpus, below the 4,641-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (14% lower).
The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Opioid Used Disorder Risk Assessment is the first listed.
NCT07135323 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT07135323 about?
NCT07135323 is a clinical study titled "AvertD Post-Approval Study". A Prospective Post-Approval Study of AvertD to Evaluate Device Performance, Prescribing Impact, and Labeling Comprehension in the Intended Use Population
What is the current status of trial NCT07135323?
This trial is currently recruiting. The enrollment target is 4,000 participants. The study started on 2024-11-15. Estimated completion is 2031-11.
What conditions does trial NCT07135323 study?
This clinical trial studies the following conditions: Opioid Use Disorder.
What interventions are being tested in trial NCT07135323?
The interventions under investigation include: Opioid Used Disorder Risk Assessment (GENETIC).
Who is sponsoring clinical trial NCT07135323?
This trial is sponsored by Prescient Medicine Holdings, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07135323 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07135323's enrollment target sits among peer trials
4,000 10th of 257 higher than 248 of 257 other Opioid Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents
RECRUITING · NA
-
Development of an mHealth Behavioral Sleep Medicine Intervention for Use During Medication Assisted Treatment for MOUD
RECRUITING · NA
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Systems Analysis and Improvement to Optimize Opioid Use Disorder Care Quality and Continuity for Patients Exiting Jail
RECRUITING · NA
-
Focused Ultrasound for the Complex Patient
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00227253 · 4,000 participants
Chromosome 18 Clinical Research Center
- NCT00811148 · 4,000 participants
Florida Center for Brain Tumor Research
- NCT00897117 · 4,000 participants
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
- NCT00899301 · 4,000 participants
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI